Ribociclib - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Ribociclib

Brand Name:

Kisqali

Strength:

200 mg

HCPCS:

NA

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Cyclin Dependent Kinase Inhibitor

Minor Drug Class:

CDK 4/6

Oral (Y/N):

Yes

FDA Approval Year:

2017

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use